Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for severe COVID-19 pneumonia requiring non-invasive ventilation
IRCT20220508054780N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) and pneumonia comparing Standard care plus baricitinib with Standard care plus placebo (2 arms). Primary endpoints: Mortality rate, APACHE II score and 17 more. Started Oct 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on IRCT20220508054780N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220508054780N1.